"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 8 | 8 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 8 | 8 |
| 2014 | 1 | 8 | 9 |
| 2015 | 1 | 7 | 8 |
| 2016 | 3 | 7 | 10 |
| 2017 | 1 | 8 | 9 |
| 2018 | 3 | 9 | 12 |
| 2019 | 1 | 4 | 5 |
| 2020 | 2 | 11 | 13 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 3 | 4 |
| 2025 | 1 | 7 | 8 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Kumar S, Mallett A, Olsen S, Coleman A. A holistic approach for quantifying the value of public health programs: social return on investment (SROI) analysis of a mobile clinic as an example. Front Public Health. 2026; 14:1650485.
-
Hoang T, Park H, Han Y, Jang JY, Shin A, Sohn H. A systematic review of economic evaluation in pancreatic cystic neoplasms. HPB (Oxford). 2026 Feb; 28(2):119-132.
-
Adjei K, Diaby V, Li M, Sherbeny F, Suther S, Ali AA. A systematic review of the applications of the real option value of medical technologies in oncology. J Manag Care Spec Pharm. 2025 Oct; 31(10):1062-1074.
-
Rakocevic LI, Alcal? RI, Goosens KA, Friedman A. Protocol for measuring context-dependent cost-benefit decision-making in humans using a web application. STAR Protoc. 2025 Dec 19; 6(4):104077.
-
Fuady A, Kasempa C, Lucas E, Nyambe N, Rao DW, Tenet V, Broutet N, Muwonge R, Mwanahamuntu M, Baussano I, Parham GP, Basu P. Economic evaluation of thermal ablation compared to cryotherapy and loop diathermy in a screen-and-treat approach to cervical cancer, Zambia. Bull World Health Organ. 2025 Sep 01; 103(9):530-540.
-
Sanogo V, Saud Almutairi RD, Diaby V. Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis. Expert Rev Pharmacoecon Outcomes Res. 2025 Dec; 25(10):1421-1426.
-
Janda K, King B, Adepoju O, Chavez S, Bejarano G, Braun RT, Ho V, Liaw W. Consolidation in an Era of Population Health and Value-Based Care: Implications for Effectiveness, Costs, and Equity. Med Care. 2025 Apr 01; 63(4):267-269.
-
Diaby V, Pandey S, Sanogo V, Dhayan Almutairi R, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):53-59.
-
Diaby V, Pandey S, Sanogo V, Almutairi RD, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):60-67.
-
MacLeod KE, Roy K, Wirth D, Minaya-Junca J, Onwuanyi A, Luo F, Lane R. The Program Cost Effectiveness of a Safety-Net Hospital Program Expanding Social Needs Activities in Atlanta. J Health Care Poor Underserved. 2025; 36(1):167-179.